Literature DB >> 1462712

[HIV infection: feasibility of a seroprevalence study with consent of hospitalized patients].

L Saghafi1, A Maziero, P Francioli.   

Abstract

A pilot study was carried out in order to evaluate the feasibility of determining the seroprevalence rate of HIV infection and the prevalence of risk factors among selected hospital patients at the Centre Hospitalier Universitaire Vaudois (CHUV). Consent was obtained and only blood already obtained for other purposes was used for testing. Among 850 patients between 16 and 65 years of age and residing in Switzerland who were originally selected at random, only 200 patients were accessible for an interview and for whom blood was available in order to be included in the study. Of these, 165 (83%) accepted their blood to be tested. A seropositive result was identified in 2 patients already aware of their serostatus. The age distribution, diagnosis and behavioral risk factors (when available through the interview) were not different among those accepting the test and the ones refusing. However, foreigners were more likely to refuse the blood test than Swiss nationals, even though none of them came from a country with a high rate of endemicity for HIV infection. Reasons for refusal included the following: lack of risk factors 10 (29%), doubts about confidentiality 6 (17%), blood test already performed 5 (14%), language barrier 4 (11%) and others 10 (29%). We conclude that even though the data in our sample did not suggest that patients refusing the test were at an increased risk of being seropositive, it is unlikely that with such a refusal rate, a reliable measure of seroprevalence could be determined in the population of study with the methods used, especially when one is expecting a relatively low seroprevalence rate.

Entities:  

Mesh:

Year:  1992        PMID: 1462712     DOI: 10.1007/bf02344186

Source DB:  PubMed          Journal:  Soz Praventivmed        ISSN: 0303-8408


  5 in total

1.  Failure of voluntary testing for human immunodeficiency virus to identify infected parturient women in a high-risk population.

Authors:  K Krasinski; W Borkowsky; D Bebenroth; T Moore
Journal:  N Engl J Med       Date:  1988-01-21       Impact factor: 91.245

Review 2.  Monitoring the prevalence of HIV.

Authors:  O N Gill; M W Adler; N E Day
Journal:  BMJ       Date:  1989-11-25

3.  The family of HIV seroprevalence surveys: objectives, methods, and uses of sentinel surveillance for HIV in the United States.

Authors:  M Pappaioanou; T J Dondero; L R Petersen; I M Onorato; C D Sanchez; J W Curran
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

4.  Pilot study of a household survey to determine HIV seroprevalence.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1991-01-11       Impact factor: 17.586

5.  Comparison of HIV-antibody prevalence in patients consenting to and declining HIV-antibody testing in an STD clinic.

Authors:  H F Hull; C J Bettinger; M M Gallaher; N M Keller; J Wilson; G J Mertz
Journal:  JAMA       Date:  1988-08-19       Impact factor: 56.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.